CA2223435A1 - Use of benzimidazoles for the manufacture of a medicament for the treatment of leukemia - Google Patents

Use of benzimidazoles for the manufacture of a medicament for the treatment of leukemia Download PDF

Info

Publication number
CA2223435A1
CA2223435A1 CA002223435A CA2223435A CA2223435A1 CA 2223435 A1 CA2223435 A1 CA 2223435A1 CA 002223435 A CA002223435 A CA 002223435A CA 2223435 A CA2223435 A CA 2223435A CA 2223435 A1 CA2223435 A1 CA 2223435A1
Authority
CA
Canada
Prior art keywords
benzimidazole
group
carbon atoms
less
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002223435A
Other languages
English (en)
French (fr)
Inventor
James Berger Camden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2223435A1 publication Critical patent/CA2223435A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA002223435A 1995-06-07 1996-05-22 Use of benzimidazoles for the manufacture of a medicament for the treatment of leukemia Abandoned CA2223435A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47381795A 1995-06-07 1995-06-07
US08/473,817 1995-06-07

Publications (1)

Publication Number Publication Date
CA2223435A1 true CA2223435A1 (en) 1996-12-19

Family

ID=23881113

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002223435A Abandoned CA2223435A1 (en) 1995-06-07 1996-05-22 Use of benzimidazoles for the manufacture of a medicament for the treatment of leukemia

Country Status (17)

Country Link
EP (1) EP0831816A1 (es)
JP (1) JPH11506732A (es)
KR (1) KR19990022617A (es)
CN (1) CN1186433A (es)
AR (1) AR003137A1 (es)
AU (1) AU717382B2 (es)
BR (1) BR9608730A (es)
CA (1) CA2223435A1 (es)
CZ (1) CZ391197A3 (es)
HU (1) HUP9802634A3 (es)
IL (1) IL118424A0 (es)
NO (1) NO975660L (es)
PL (1) PL324026A1 (es)
SK (1) SK168697A3 (es)
TR (1) TR199701536T1 (es)
WO (1) WO1996040122A1 (es)
ZA (1) ZA964373B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
EP2251010A1 (en) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Use of thiabendazole and derivatives thereof for the therapy of neurological conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL134354C (es) * 1963-05-23
FR2155888A1 (en) * 1971-10-13 1973-05-25 Agot Aime Solid anthelmintic composn - for more economical treatment of ruminants

Also Published As

Publication number Publication date
NO975660D0 (no) 1997-12-05
JPH11506732A (ja) 1999-06-15
AR003137A1 (es) 1998-07-08
AU5802096A (en) 1996-12-30
PL324026A1 (en) 1998-05-11
IL118424A0 (en) 1996-09-12
EP0831816A1 (en) 1998-04-01
WO1996040122A1 (en) 1996-12-19
TR199701536T1 (xx) 1998-02-21
NO975660L (no) 1998-02-09
AU717382B2 (en) 2000-03-23
KR19990022617A (ko) 1999-03-25
SK168697A3 (en) 1998-12-02
CZ391197A3 (cs) 1998-05-13
HUP9802634A2 (hu) 1999-03-29
ZA964373B (en) 1996-09-02
HUP9802634A3 (en) 1999-05-28
CN1186433A (zh) 1998-07-01
BR9608730A (pt) 1999-06-29

Similar Documents

Publication Publication Date Title
CA2217952C (en) A pharmaceutical composition containing benzimidazole for inhibiting the growth of cancers
CA2223435A1 (en) Use of benzimidazoles for the manufacture of a medicament for the treatment of leukemia
US5665751A (en) Pharmaceutical composition for inhibiting the growth of cancers
US5767138A (en) Pharmaceutical composition for inhibiting the growth of viruses and cancers
RU2330661C2 (ru) Комбинации, включающие антидиарейный агент и эпотилон или производные эпотилона
KR20000070551A (ko) 화학 요법제 및 벤즈이미다졸, 및 선택적으로 강화제를 함유하는 암세포 성장 억제용 키트
EA022119B1 (ru) Комбинированная терапия раковых заболеваний с помощью соединений - ингибиторов hsp90
US6228876B1 (en) Pharmaceutical composition for inhibiting the growth of cancers
CA2268848A1 (en) Hiv and cancer treatment
EP0820281B1 (en) A pharmaceutical composition containing n-chlorophenylcarbamates and n-chlorophenylthiocarbamates for inhibiting the growth of viruses
MXPA97007809A (es) Una composicion farmaceutica que contiene bencimidazol para inhibir el crecimiento de canceres
AU6521000A (en) Method of cancer treatment
JP2017538767A (ja) 毛包虫症治療のためのイソオキサゾリン化合物の使用
MXPA97009833A (es) Uso de benzimidazoles para la fabricacion de un medicamento para el tratamiento de leucemia
JPH03504506A (ja) 蠕虫感染症の治療または予防用の医薬および動物薬組成物
MXPA99006961A (es) Estuche para inhibir el crecimiento de canceres,que comprende un agente quimioterapeutico y un bencimidazol, y opcionalmente un potenciador
MXPA97009530A (es) Uso de bis-1,2.4-triazoles para la manufactura deun medicamento para el tratamiento de cance
JPH049333A (ja) 動物の寄生虫駆除剤
AU3879001A (en) Hiv and cancer treatment
MXPA97009712A (es) Uso de derivados de 1,2,4-triazol para la manufactura de un medicamento para el tratamiento de canceres

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued